Canaccord analyst John Young raised the firm’s price target on Merit Medical to $112 from $102 and keeps a Buy rating on the shares. The firm believes with a continued focus on both operating margin improvement and FCF generation, management continues to aim to expand value for shareholders.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MMSI:
- Merit Medical Systems Unveils Growth Plans in Earnings Call
- Merit Medical Reports Results For Fourth Quarter and Year Ended December 31, 2023 – Issues Fiscal Year 2024 Guidance
- Merit Medical Introduces “Continued Growth Initiatives” Program and Financial Targets for Three-Year Period Ending December 31, 2026
- MMSI Earnings this Week: How Will it Perform?
- Merit Medical Receives FDA 510(k) Clearance for SCOUT® MD™ Surgical Guidance System
